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ith almost 5 million new 
HIV infections and 3 million 
deaths from AIDS occurring 
every year worldwide, the development 
of a safe, effective, and accessible HIV 
vaccine has become one of the most 
urgent global public health needs. 
The United Nations estimates that 
17.5 million women between the ages 
of 15 and 49 years are living with HIV, 
accounting for nearly half of the 40.3 
million infections worldwide [1]. These 
ﬁ  gures reveal the increasingly female 
face of AIDS. 
    As with many diseases, women in 
developing countries are particularly 
vulnerable to HIV. Poverty—and 
women’s necessary reliance on men for 
economic subsistence—may force some 
women to exchange sex for money 
or material favors. Women in some 
cultures lack access to information 
on protection from and treatment of 
sexually transmitted infections. There 
may be societal pressures for women to 
have children, thereby affecting their 
use of contraception. Also, in many 
settings, women and girls lack the 
ability to negotiate safe sex or demand 
ﬁ  delity in a relationship. For most 
women in these situations, it is not 
their own behavior but the behavior of 
their partners that puts the women at 
risk of sexually transmitted infections, 
including HIV [2]. The possibility of 
a preventive HIV vaccine, therefore, 
holds tremendous promise for women. 
    Despite the epidemiologic reality, 
women have had minimal participation 
in HIV vaccine trials [2]. To develop 
HIV vaccines with regional efﬁ  cacy, it is 
important to identify and characterize 
the viruses that are transmitted, in 
particular to individuals living in areas 
and conditions of high incidence. 
Enrolling women in HIV vaccine trials 
represents an important challenge that 
must be fulﬁ  lled in order to conduct 
ethical, valid, and generalizable trials 
[3–5]. 
    Women’s Concerns about Enrolling 
in HIV Vaccine Trials
    Efforts to enroll and retain women 
in trials begin by recognizing that 
their expectations and requirements 
for participation may be different 
from those of men. Women may 
lack the decision-making freedom to 
participate in a trial, especially a trial 
that addresses sexual behavior. They 
may be burdened with childcare and 
a lack of transportation. For women 
with children, participation is often 
limited by having to attend one of the 
few trial sites that offer childcare [6]. 
Indeed, trials requiring that pregnancy 
and breast-feeding be avoided may 
place undue stress upon participants in 
cultures that place value on women’s 
fertility.
     Some cultural barriers identiﬁ  ed in 
the recent HIV vaccine candidate trial 
in Kenya included women’s belief that 
a woman of childbearing age who uses 
contraceptives is giving her husband 
an excuse to look for another woman 
with whom to bear children [7]. On 
the other hand, men believed that 
childbearing was a way of keeping 
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  Box 1. Important Barriers 
to Enrolling Women in HIV 
Vaccine Trials 
    Women’s enrollment may be hindered 
by their fears or concerns about the 
following:
    •  Contracting HIV from the vaccine
    •  Testing positive for antibodies to HIV
    •  The effect of the vaccine upon future 
pregnancies
    •  Appearing to distrust one’s partner
    •  Mistakenly being viewed as HIV-
infected
    •  Their partner refusing sex due to the 
woman’s involvement in the trial
    •  Inadvertent disclosure of trial 
participation
    •  Discrimination against participant by 
family
    •  Being refused entry into countries, or 
difﬁ  culties with immigration, if they 
test positive for antibodies to HIV
  •  Potential  job  loss
    •  The possibility of receiving a placebo
    •  Being able to obtain insurance if they 
are infected during the trial
    •  The lack of convenient clinic hours 
for mothers, houseworkers, and sex 
workers PLoS Medicine  |  www.plosmedicine.org 0309
women from inﬁ  delity. Condoms, 
which were recommended for use 
during the trial, were perceived as 
instruments to promote extramarital 
relationships. 
    To identify and tackle such barriers 
(Box 1), trial staff require gender-
speciﬁ  c guidance and training, while 
recruitment materials should be 
geared toward both sexes. Supplying 
trial centers with counselors and staff 
who are sensitive to gender, class, 
and cultural barriers may improve 
women’s access to HIV vaccine trials. 
Allowing ﬂ  exible clinic hours to meet 
the speciﬁ  c needs of patients is one 
of many pragmatic solutions resulting 
from such sensitivity training.
    Fear of Adverse Events
    Participants in HIV vaccine trials 
often fear that they will become HIV-
positive through participation, either 
through infection from the vaccine 
or from antibodies produced by the 
vaccine, which would test positive 
in some test kits [8–10]. A speciﬁ  c 
female concern is the unknown effects 
on future pregnancies [11,12]. This 
fear is compounded by the concern 
among women that they may be unable 
to travel or to attain insurance or 
employment if they test positive as a 
result of the vaccine [8]. 
    At least some of these fears could 
be allayed by community participation 
in the form of community advisory 
boards and the engagement of local 
community representatives in designing 
educational materials to educate the 
medical community and population at 
large [13]. 
  Informed  Consent
    Obtaining consent is a further challenge 
in some female populations, as women 
in poorer countries often lack formal 
education and may not understand the 
uncertainty that exists within clinical 
trials (the therapeutic fallacy) [14]. 
The principle of informed consent is 
that consent is freely given, without 
coercion from trialists or the local 
community [15]. Therefore, all trial-
related information should be presented 
in the local language, and should 
address varying levels of education in 
both written and oral presentation so 
that participants fully understand their 
rights, risks, and potential beneﬁ  ts. 
Participants need to be questioned on 
their understanding of the trial process 
[2]. The informed-consent sheets 
should be prepared in consultation 
with the community advisory board and 
piloted within the target community to 
ensure gender and social sensitivity.
  Conﬁ  dentiality
    The International AIDS Vaccine 
Initiative (http://www.iavi.org) has 
elucidated the basic requirements of 
the physical setting required of trial 
sites (Box 2) [2]. However, ensuring 
conﬁ  dentiality is a challenge in centres 
that are in public view. For women, 
any breach of conﬁ  dentiality can 
lead to increased discrimination and 
harassment. Women may be subjected 
to violence or abandonment by their 
male partners or to discrimination 
from their employers if they are 
seen entering trial centres. Other 
implications include the refusal of sex 
as a result of a woman’s presumed risky 
lifestyle [16]. Safeguards to maintain 
conﬁ  dentiality must therefore be in 
place. Diagnostic tests should only 
be disclosed to the participant, and 
supportive counseling should be 
provided before and after the tests, 
regardless of the frequency of HIV tests 
required. 
    Barriers Faced by Sex Workers
    Sex workers, due to the nature of their 
work, experience additional concerns. 
In addition to difﬁ  culties related to 
informed consent, conﬁ  dentiality, 
and fear of infection, sex workers may 
experience continual exposure to 
coarse client interactions and violence. 
Sex workers thus require services that 
address both domestic abuse and 
client-related violence. They should 
also receive educational sessions 
on common myths about safe sex, 
including false information that may 
be given to them by their employers 
or partners [17]. Education efforts 
regarding safe sex should not just 
involve the trial participants but also 
their clientele. To accomplish this, the 
promotion of condom use and safe sex 
in the commercial sex districts and bars 
frequented by the clientele is required. 
Studies have shown that many women 
require permission from their partners 
and employers to undergo HIV testing, 
at times at the risk of violence [18,19]. 
Education aimed at sex workers’ 
partners and employers could make 
this process more socially acceptable. 
  Beneﬁ  ts of Participation
    Considering the social risks of HIV 
vaccine trial participation, the 
immediate beneﬁ  ts to women are small; 
efforts to recognize their participation 
begin by appreciating the value of their 
role. The beneﬁ  ts that might arise from 
participation include the potential 
that HIV education may reduce the 
risk of infection and that participants 
March 2006  |  Volume 3  |  Issue 3  |  e94
DOI: 10.1371/journal.pmed.0030094.g001 
  Figure 1.   HIV Vaccine Awareness Day at the AIDS Community Health Initiative Enroute to a 
Vaccine Effort (Project ACHIEVE), 18 May 2005 
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might receive health care and 
contraceptive advice that would not 
normally be provided in communities 
where health services are limited. We 
should, however, recognize that despite 
education on safer sex for women, safe 
sex is most often determined by their 
partners’ behavior [2].
    Conducting valid and generalizable 
HIV vaccine trials requires the 
equitable inclusion of women. Barriers 
for participation of women are often 
systematically different from barriers 
for men, since the barriers to women 
stem from their often lower social 
status and lack of decision-making 
rights. Due to the number of different 
HIV clades, trials need to be conducted 
in a variety of cultures and classes. 
Although differences in women’s 
rights exist between varying cultures 
[20], most often in settings with high 
HIV prevalence, women suffer from 
a lack of empowerment in health and 
the possibility of violence or social 
discrimination for being involved 
with people living with HIV/AIDS 
or participating in a trial of this 
unmentionable subject.
    In order to conduct clinically 
meaningful subgroup analyses, a 
large enough sample of the planned 
subgroup must be available, with 
adequate power to detect an effect. 
To ensure adequate power within 
the trial participants, the participants 
must be at risk of infection [21]. Thus, 
enrolling females at high risk in HIV-
endemic regions allows room to make 
important clinical inferences, but puts 
these individuals in potentially risky 
situations [22]. 
    Recommendations to support 
gender recognition and sensitivity are 
often provided for staff allied to the 
trial (such as coordinating clinic staff). 
Efforts to create a speciﬁ  c, gender-
sensitive, and informed consent process 
are undermined if the manner with 
which the consent is presented or 
obtained is not respectful and inclusive 
of the target community. Gender 
advisors and community advisory 
boards made up of key informants 
from the risk groups can inform 
education efforts aimed at potential 
trial participants [2]. We acknowledge 
that cultural differences in women’s 
rights can be extreme, and that in-
depth knowledge of the community, 
where the trial is being conducted, is 
imperative to understanding barriers 
to participation. This article, and those 
identiﬁ  ed elsewhere [2,9,12, 23–28], 
should be considered basic reading 
in preparation for designing trial 
protocols and recruitment strategies.
    Recruitment efforts to include at-risk 
women in HIV vaccine efﬁ  cacy trials are 
diverse, and require active involvement 
of community agencies. Successfully 
retaining these women over time 
presents ongoing challenges that relate 
to the trial validity, which will need 
to be addressed to ensure women’s 
involvement in future trials [29]. The 
AIDS Community Health Initiative 
Enroute to a Vaccine Effort (Project 
ACHIEVE), a vaccine preparedness 
study in New York City’s South Bronx 
area (Figure 1), successfully retained 
92% of women enrolled after one 
year [24]. Similar retention rates have 
been replicated in HIV vaccine trials 
with similar cohorts of women in New 
York. Concerns about retaining hard-
to-reach populations should not cause 
the exclusion of high-risk women from 
HIV vaccine and other prevention trials 
[30].
    The recent cessation of the 
tenofovir pre-exposure prophylaxis 
trials in sex workers in Cambodia 
and Cameroon demonstrates the 
difﬁ  culties of ensuring the rights of the 
enrolled participants [13,31,32]. The 
trials closed early due to widespread 
complaints that the participant 
communities had not been involved in 
the planning of the trials. The events 
that halted the trials exemplify the 
need to involve the target groups in the 
planning of prevention trials [33]. 
    Researchers as Human Rights 
Advocates
    We (EM, SS) recently advocated for 
the development of standards for 
community advisory boards [13], such 
as exist for ethical review committees, 
so that efforts to engage the target 
populations will transcend tokenism. 
We recognize that this concept will 
be new for many clinical trialists. We 
believe that researchers, by the nature 
of their work, should be advocates 
for the rights and protection of trial 
participants, and in communities 
and countries where the rights of the 
participants are threatened, researchers 
should determine if it is appropriate 
to engage in research there and seek 
assistance from human rights monitors 
when there is uncertainty. The 
development of trial protocols needs 
to consider accounts of violence and 
human rights violations, and develop 
a strategy for improving conditions for 
individuals or communities affected.
    Today’s AIDS research uses 
technologies that may be exciting 
from a scientiﬁ  c standpoint but are 
challenging when we consider the risks 
participants may incur by participation. 
Many high-risk communities are 
ready to assist in research, but 
researchers must be prepared to 
assist the communities beyond the 
trial’s duration and ensure that local 
standards of medical care are improved 
through the research itself and also 
through the presence of researchers 
who advocate on participants’ behalf.
  Conclusion
    Enrolling women in HIV vaccine trials 
worldwide represents an important 
challenge. Ensuring that the rights 
and needs of this population are 
respected and met requires community 
involvement and representation. 
Researchers must be sensitive to the 
needs of high-risk and vulnerable 
groups, from the initial stages of the 
trial through to unforeseen future 
events. By implementing strategies 
to enroll and protect the high-risk 
and vulnerable participants, we can 
appreciate the enormous contributions 
they are making to science.   
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  Box 2. Basic Requirements to 
Make the Physical Environment 
of the Trial Site Gender-
Sensitive
    •  Convenient location for women to 
attend
    •  A reception area and space that would 
be unintimidating, welcoming, and 
volunteer-friendly
    •  Privacy—in terms of being neither 
seen nor heard—when interviews are 
conducted
    •  A waiting area with general space for 
families and a specially designated area 
for women and children
    •  Childcare during medical examinations 
or counseling sessions
    •  Clean toilets, a canteen, and 
appropriate audiovisual material and 
educational literature
    (Reproduced, with permission, from [2]) PLoS Medicine  |  www.plosmedicine.org 0311 March 2006  |  Volume 3  |  Issue 3  |  e94
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